Data from Study 109, a 1-year, open-label, phase II trial evaluating the safety and tolerability of EXJADE. Efficacy was measured by change in liver iron concentration (LIC) using biosusceptometry. Adjusted change (mean+SD) in LIC determined according to assigned treatment category for EXJADE.2
Follow-up for the pivotal SCD trial was extended. Learn more about the long-term data.